Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Decoding the Mechanics of Metals by Coarse-Grained Atomistics (COGRA)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Products and processes engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Switzerland
Call: ERC Consolidator Grant (ERC-2017-COG, 2017)
Start date: 2018-03-01
End date: 2024-08-31
Duration (months): 78.0
Total project cost (EUR): 1995128.0
EU funding (EUR): 1995128.0
Participants: 1
Project status: SIGNED

"First principles" and "bottom-up" have become buzz words across scientific and engineering disciplines when it comes to the discovery, prediction and understanding of material properties and their link to processing and microstructure. Reality, however, teaches us that in the foreseeable future computational resources will be insufficient to apply predictive techniques such as quantum mechanics or atomistics to the technologically most relevant length and time scales - far above nanometers and nanoseconds. This proposal aims for nothing less but the seemingly impossible: the application of atomistic techniques to problems occurring over microns to millimeters and seconds to minutes. Instead of relying on computational power, this will be achieved by a combination of scale-bridging methodologies (involving the PI's nonlocal and meshless quasicontinuum techniques, concepts from particle methods, continuum and statistical mechanics) and computational science strategies in order to produce new theory and an open-source, computational toolset for long-term, large-scale simulations relying solely on atomistic input. Spatial upscaling, temporal upscaling as well as heat and mass transfer will be addressed. Enabled by the new scale-bridging capabilities, two representative, open challenges will be investigated: recrystallization in magnesium during thermo-mechanical processing and corrosion in steel by hydrogen embrittlement. Both are of enormous technological and economic importance but current techniques are insufficient to bridge the gap between the macroscopic mechanical performance, microstructural mechanisms and predictive atomic-scale simulations. The outcomes of this five-year research program will provide never-before techniques and numerical tools to catalyze a user community across science and technology. Although the focus is on metals, several of the proposed techniques are applicable to a significantly wider range of materials and applications.

Keywords: solid mechanics,computational science
Antibiofouling Nanopatterned Electrospun Membranes for Nanofiltration Applications (ANEMONE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Ireland
Call: ERC-Proof of Concept (ERC-2017-PoC, 2017)
Start date: 2017-10-01
End date: 2019-03-31
Duration (months): 18.0
Total project cost (EUR): 148805.0
EU funding (EUR): 148805.0
Participants: 1
Project status: CLOSED

Water-stress in an increasing global problem and solutions such as water recycling and seawater desalination are now becoming a necessary part of the water infrastructure. The technology for the production of safe drinking is increasingly dependent on these more diverse sources and a key enabling technology is membrane filtration. While membrane system are effective, the operating costs of such systems are hampered by fouling which increases the energy requirement for process operation. The unique idea of this Proof of Concept is to develop an electrospun nanostructured membrane which can be integrated into water filtration technologies. The unique method of fabrication will produce an inherently antibacterial and antibiofouling surface in a one-step process, cutting the number of manufacturing steps. This concept, when deployed commercially is expected to dramatically reduce the operating costs of membrane processes for water treatment. The commercialisation route of the product will be through the patent protection and the licensing of the technology with a view to rapid commercialisation.

Keywords: water,biofouling,materials,nanofiltration,fouling,polymer
Personalized oncology for refractory and relapsed lymphoma using humanized patient derived othotopic xenografts (ImmunePDOX) (PORTAL)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-04-01
End date: 2020-03-31
Duration (months): 24.0
Total project cost (EUR): 170121.6
EU funding (EUR): 170121.6
Participants: 1
Project status: CLOSED

This proposal is a “PORTAL” to re-incorporate Dr. Lourdes Farre from the Oswaldo Cruz Foundation (FIOCRUZ) in Brazil to Europe at the Catalan Institute of Oncology (ICO), a part of the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. She will be supervised by Dr. Alberto Villanueva, leader of the Resistance, Chemotherapy and Orthotopic Xenograft Models Group and Director Board of the EuroPDX (www.europdx.eu) in collaboration with Dr. Ana Sureda, Head of the Hematology Department (ICO). Dr. Farre worked at FIOCRUZ for 12 years where she relevantly contributed in lymphoma research and acquired maturity as an independent researcher. Dr. Farre will contribute to ICO/IDIBELL initiating a new research line in resistance in hematological cancers and transfer her knowledge in HTLV-1 infection. She will also contribute to the ICO Hematology Service with a personalized oncology strategy for clinical oncology practice. Knowledge and preclinical models could be transfer to the IDIBELL`s spin-off Xenopat and Pharmaceuticals. She will have access to a solid multidisciplinary training program that will provide qualitative improvement on her career and a privileged position to be reintegrated in a long term research position in Europe. She has always combined scientific activity with educational interventions. Besides scientific dissemination, she programmed public engagement activities. This proposal is a proof-of-concept of personalized oncology for refractory/relapsed lymphoma and aims to study the mechanisms involved in response to therapy using preclinical humanized orthotopic models. Relapsed/refractory lymphomas represent a major treatment challenge and general treatment paradigm has remained empiric. Defining the best therapeutic option for each patient and overcoming such resistance is a priority. Humanized and orthotopic approach is original and innovative. PORTAL reflects the policy priorities of the Europe 2020 strategy and considers gender issues.

Keywords: lymphoma,refractoriness,personalised oncology,molecular mechanisms,orthotopic,implantation,preclinical models,htlv 1 associated diseases,bioinformatics,extracellular,vesicles,humanized models
Nucleolar regulation of longevity (NUAGE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Germany
Call: ERC Advanced Grant (ERC-2018-ADG, 2018)
Start date: 2020-01-01
End date: 2024-12-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Research over the last few decades has revealed that animal life span is malleable and regulated by conserved metabolic signaling pathways, including reduced insulin/IGF signaling, mTOR, mitochondrial function, dietary restriction, and signals from the reproductive system. Whether these various pathways converge on common processes, however, has remained elusive. We recently discovered the nucleolus to be a crucial focal point of regulation in all these pathways. The nucleolus is a subnuclear organelle dedicated to rRNA production and ribogenesis, but also controls assembly of other ribonucleoprotein complexes including spliceosomes, signal recognition particle, small RNA processing, stress granules, and responds to growth and stress signaling. Remarkably we found that small nucleoli are a cellular hallmark of longevity in diverse species, and a correlate of metabolic health in humans. At the molecular level, long-lived animals show reduced levels of the nucleolar ribosomal RNA methylase, fibrillarin (FIB-1), and knockdown of C. elegans FIB-1 reduces nucleolar size, extends life span, and enhances innate immunity. Conversely, knockout of NCL-1/TRIM2 expands nucleolar size, suppresses life extension of major longevity pathways, and renders animals pathogen sensitive, revealing key regulators of nucleolargenesis, immunity and longevity. Here I propose to (Aim 1) clarify the mechanism of action of NCL-1, FIB-1 and interacting molecules (2) perform novel genetic screens for nucleolargenesis in C. elegans (3) uncover global transcriptomic and proteomic changes induced by NCL-1 and FIB-1 and survey several candidate nucleolar processes in regulating longevity and immunity (4) probe NCL-1/TRIM2 regulation of longevity in the short-lived killifish, Notobranchius furzeri, and develop nucleolar biomarkers of metabolic health in humans. These groundbreaking studies should illuminate how conserved signaling pathways work through the nucleolus to regulate health and life span.

Keywords: caenorhabditis elegans,nucleolus
THE DEVELOPMENT OF NOVEL PHOTOSWITCHABLE KINASE INHIBITORS (RET PHOTOSWITCH)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Sweden
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-10-01
End date: 2020-09-30
Duration (months): 24.0
Total project cost (EUR): 185857.2
EU funding (EUR): 185857.2
Participants: 1
Project status: CLOSED

The overall research objective of this project is to develop novel photoswitchable kinase inhibitors (PKIs), targeting on REarrange during Transfection (RET) for use in living cells and in zebrafish (Danio rerio). Controlling the action of kinases in a reversible way will have an exceptional potential for investigating signal transduction in zebrafish. In this work, photoswitchable RET kinase inhibitors based on azo-functionalized pyrazolopyrimidines will be developed, enabling photonic control of RET activity with substantial differences in inhibitory activity between the two photoisomeric forms. Such RET inhibitors are currently not available. RET is expressed by the immune cells of the brain, the microglia and is mediating activation of the cells. Microglia has been shown to be responsible for both protecting and harmful effects in neurodegenerative disorders. Although RET has been shown to be involved in neurodegeneration, its role in Alzheimer’s disease (AD), where microglia play an important role, is not known. The ability to manipulate the activity of RET using light would result in temporal control of enzymatic activity, thus serving as a valuable molecular tool to study the function of RET in microglia cells and further our understanding of AD. The research project is (1) highly interdisciplinary, (2) timely due to the recent interest of photopharmacology and (3) innovative by combining zebrafish imaging with photopharmacology to study signalling relevant for development of AD. This fellowship will ensure the best possible career opportunities for me as I will receive substantial training in cutting-edge approaches, gain mentor and supervision skills, presentation skills and critical assessment skills, largely expand my collaborative network, and gain the fundaments for becoming a mature, independent researcher within the field of chemical biology.

Keywords: rearrange during transfection ret,photoswitchable kinase inhibitors,photoisomerisation,zebrafish,alzheimer s disease ad
Reconstructing cellular histories with transcriptional recording (CRISPRhistory)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Biotechnology and Biosystems Engineering
Panel description: Biotechnology using all organisms, biotechnology for environment and food applications, applied plant and animal sciences, bioengineering and synthetic biology, biomass and biofuels, biohazards
Countries involved: Switzerland
Call: ERC Starting Grant (ERC-2019-STG, 2019)
Start date: 2019-12-01
End date: 2024-11-30
Duration (months): 60.0
Total project cost (EUR): 1499564.0
EU funding (EUR): 1499564.0
Participants: 1
Project status: SIGNED

What are the main differences between a photograph and a video? Photographs record a single point in time and videos continuously record a sequence of events. While the content and interpretation of a photograph is heavily reliant on a single moment in time, a video is not. The tools that scientists have to understand the molecular and cellular world around them are most like film cameras – producing single snapshots to describe dynamic processes. Towards the goal of continuously recording molecular events within cells, my laboratory recently developed ‘transcriptional recording’, an approach that employs CRISPR spacer acquisition from RNA to capture and convert intracellular RNAs into DNA, permanently storing transcriptional information in the DNA of living cells. The newly acquired sequences serve as transcriptional records, which are retrievable via deep sequencing and can be leverage to reconstruct cellular histories. This technology provides an entirely new mode of interrogating dynamic biological and physiological processes and opens up numerous avenues for future work. The overall goal of this proposal is to develop transcriptional recording sentinel cells with the capacity to continuously monitor biological and pathological processes within the mammalian gut. To achieve this goal, we will employ a variety of methods that include molecular and cellular biology, synthetic biology, protein engineering, bioinformatics, and mouse models. We will focus our efforts on improving the efficiency of transcriptional recording, combining transcriptional recording with biosensing gene circuits, and demonstrating that transcriptional recording sentinel cells facilitate interrogation of the mammalian gut environment and can be applied as a living diagnostic. In summary, this study lays the foundation for developing a fundamentally new approach to interrogating dynamic biological and pathological processes as well as engineering living diagnostics.

Keywords: crispr cas biology,crispr spacer acquisition,synthetic biology and cellular memory genetic circuits,deep sequencing,functional genetics,protein engineering and directed evolution,microbial based living diagnostics
Arrhythmias monitoring and comprehensive care (RITMOCORE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: Public Procurement of Innovative Solutions
Countries involved: Spain,Italy,Italy,Spain,Netherlands,Netherlands,United Kingdom,United Kingdom
Call: PPI for deployment and scaling up of ICT solutions for active and healthy ageing (H2020-SC1-2016-CNECT, 2016)
Start date: 2016-11-01
End date: 2022-07-31
Duration (months): 69.0
Total project cost (EUR): 11750553.81
EU funding (EUR): 4112693.83
Participants: 11
Project status: CLOSED

RITMOCORE is addressing the evolution in the treatment of elderly patients with arrhythmias using or in need of a pacemaker. The proposed approach promotes a comprehensive model of care including: empowerment of general practitioners and integration of care pathways through the adequate information sharing; remote monitoring of pacemakers; home monitoring of vital signs using wearables, Apps and available innovative devices; patient activation and increases the alignment of objectives among all involved stakeholders (providers, doctors, Hospital managers, patients). To achieve these goals RITMOCORE proposes to move from a conventional purchasing of devices to an innovative service provision able to complement the resources of the public service providers including: support center for remote monitoring of pacemakers, delivering of pre-defined information sets to all stakeholders and professionals involved in the care path, integration and quality labeling of vital signs home monitoring devices and wearables and support for patient activation. The service will be based on a risk sharing model. Several partners of RITMOCORE are already working together on STOPandGO, a PPI addressing the development of a European Specification Template and a Reference Business Case for innovative ICT-enabled services for elderly people, being validated in 7 procurements. The experience of STOPandGO has been extremely enlightening on the main difficulties in addressing a PPI and the STOPandGO results will be used to shape the Business Case and the High Level Specifications in RITMOCORE. RITMOCORE procurers are leading cardiac care hospitals: Sant Pau in Barcelona (Spain), Liverpool Heart and Chest NHS Hospital (UK), Elisabeth-TweeSteden Hospital (NL) and the Regional Healthcare Trust of the Marche Region, with its hospital in Fermo (IT).

Keywords: arrhythmia,remote monitoring,prevention,risk sharing procurement
Designing cooperative interaction of automated vehicles with other road users in mixed traffic environments (interACT)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Italy,Germany,Greece,United Kingdom
Call: Safety and end-user acceptance aspects of road automation in the transition period (H2020-ART-2016-Two-Stages, 2016)
Start date: 2017-05-01
End date: 2020-09-30
Duration (months): 41.0
Total project cost (EUR): 5527581.25
EU funding (EUR): 5527581.25
Participants: 8
Project status: CLOSED

There is currently a high desire by manufacturers to introduce Automated Vehicles (AVs), SAE level 3 and above, to the market. As AVs are likely to be deployed in mixed traffic, they need to interact safely and efficiently with other (non-equipped) users, including manually driven vehicles, cyclists and pedestrians. Although obstacle detection by AVs is almost flawless, these vehicles cannot communicate their intentions to other road users. This limitation currently reduces their appeal and value to the user. To ensure intuitive and cooperative interaction between the AV and others, and a smooth flow of all traffic, it is essential that there is good means of communication between all actors. The main objective of interACT is to substantially improve this communication and cooperation strategy. interACT will provide an overview of current human-machine interactions in mixed traffic, and increase chances of safe deployment of AVs by developing novel software and HMI hardware components for reliable and user-centric communication between an AV with its users. interACT will: 1) Use social-psychological models to compile a catalogue of interactions, identifying the main communication needs of road users in current and future traffic scenarios 2) Improve software algorithms and sensor capabilities for assessing intention recognition and behaviour prediction of surrounding road users 3) Use a Cooperation and Communication Planning Unit to integrate planning algorithms, providing synchronized and integrated communication protocols 4) Ensure safety of road users by developing easy-to-verify software for a safety layer, and novel methods for fail-safe trajectory planning. Prototypes will be developed and evaluated in multi-actor simulators and two test vehicles, assessing ease-of-use, acceptance, safety and reliability. The impact of this successful communication on reduction of crashes, improvement of traffic flow and acceptance of AVs by society will be investigated.

Keywords: psychological interaction models,improved intention recognition,fail safe manoeuvre planning algorithms,human centred design solutions,inuitive,highly accepted interaction,novel light based hmi
The Evolution of PRDM9 Binding and Genomic Localization of Meiotic Recombination Events (PRDM9Recomb)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-05-01
End date: 2017-04-30
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

Meiotic recombination is an essential process for sexually reproducing organisms. The appropriate genomic distribution of recombination events is necessary for the accurate transmission of genetic information from one generation to the next. Extensive research has demonstrated that a major determinant of recombination sites in mice and humans is the DNA-binding protein PRDM9. An intriguing feature of PRDM9 is the exceptionally rapid evolution of its DNA-binding domain, which causes enormous variability in the locations of recombination events, even within a single species. To date, our understanding of PRDM9’s genome-wide distribution is based largely on its predicted DNA-binding specificity, however, the presence of a predicted consensus motif alone is not a strong predictor of recombination locations. Here, I will test the hypothesis that additional factors act in concert with the rapidly evolving PRDM9 protein to specify sites of meiotic recombination events. I will directly map and compare the genome-wide distribution of PRDM9 in different mouse strains to understand the evolution and principles of its binding. I will also pioneer a single-cell based approach that can distinguish between different classes of recombination events to build a high-resolution genome-wide recombination map to further dissect the role of PRDM9, and to identify additional factors, that shape the recombination landscape.

Keywords: prdm9,meiotic recombination,meiosis,comparative genomics,evolution,mouse